Author, year | Institution(s)/ Database | Population | Time intervals | Comments |
---|---|---|---|---|
Andre, 2004 [5] | France (3 institutions) | 724 women de novo metastatic breast cancer | 1987-1993 | Excluded supraclavicular lymph node only patients. Improved 3 year overall survival (OS; 44% vs 27%) was seen in the more recent time period. |
 |  |  | 1994-2000 |  |
Giordano, 2004 [9] | MD Anderson Cancer Center | 834 women with recurrence after adjuvant doxorubicin | 1974-1979 | Included patients with locally recurrent disease. Predictors of improved overall survival included stage at diagnosis, interval disease-free survival, and dominant metastatic site. |
 |  |  | 1980-1984 |  |
 |  |  | 1985-1989 |  |
 |  |  | 1990-1994 |  |
 |  |  | 1995-2000 |  |
Chia, 2007 [6] | British Columbia Cancer Agency | 2150 women with both recurrent and de novo metastatic breast cancer | 1991-1992 | An improvement in overall survival was noted over time, primarily in those patients that were hormone-receptor positive. |
 |  |  | 1994-1995 |  |
 |  |  | 1997-1998 |  |
 |  |  | 1999-2001 |  |
Dawood, 2008 [13] | Surveillance, Epidemiology, and End Results Registry | 15,438 women with both recurrent and de novo metastatic breast cancer | 1988-1993 | There was a modest improvement in overall survival, associated with patients with hormone-receptor positive disease. Outcomes appeared to be worse in African American women. |
 |  |  | 1994-1998 |  |
 |  |  | 1999-2002 |  |
 |  |  | 2003-2006 |  |
Dafni, 2009 [14] | Hellenic Cooperative Group | 1361 enrolled on trials for treatment of recurrent and de novo metastatic breast cancer | 1991-1994 | Trastuzumab used in 24% and 30% of patients in the two most recent time intervals. |
 |  |  | 1995-1998 |  |
 |  |  | 1999-2003 |  |
Ruiterkamp, 2011 [10] | Netherlands | 8031 women with both recurrent and de novo metastatic breast cancer | 1995-1999 | 10% of patients in third time interval received targeted therapy. |
 |  |  | 2000-2004 |  |
 |  |  | 2005-2008 |  |
Pal, 2011 | City of Hope | 274 de novo metastatic breast cancer only | 1985-1994 | Overall survival improved for those receiving endocrine therapy, but no apparent overall survival benefit with newer chemotherapeutic agents. |
 |  |  | 1995-2004 |  |